Literature DB >> 10196344

Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques.

L Mortara1, H Gras-Masse, C Rommens, A Venet, J G Guillet, I Bourgault-Villada.   

Abstract

We have optimized the induction of antiviral cytotoxic T lymphocytes (CTL) in rhesus macaques by a lipopeptide vaccine containing seven peptides from simian immunodeficiency virus (SIV) Nef and Gag proteins and a strong T-helper peptide from tetanus toxoid (TT) that is promiscuous in humans (peptide TT 830-846). Two of the eight immunized macaques showed T-helper (Th) cell proliferation and a specific synthesis of gamma interferon in response to TT 830-846 peptide. They also showed multispecific cytotoxic activity against three to five of the immunizing SIV peptides. These results show the importance of a strong specific type 1 Th response for inducing a multispecific CTL response in vivo, which is essential for the development of an anti-human immunodeficiency virus vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196344      PMCID: PMC104228     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

2.  Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL.

Authors:  B Deprez; J P Sauzet; C Boutillon; F Martinon; A Tartar; C Sergheraert; J G Guillet; E Gomard; H Gras-Masse
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

3.  Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides.

Authors:  J P Sauzet; H Gras-Masse; J G Guillet; E Gomard
Journal:  Int Immunol       Date:  1996-04       Impact factor: 4.823

4.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

5.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

6.  Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets.

Authors:  G Stuhler; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

7.  Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo.

Authors:  M F del Guercio; J Alexander; R T Kubo; T Arrhenius; A Maewal; E Appella; S L Hoffman; T Jones; D Valmori; K Sakaguchi; H M Grey; A Sette
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

8.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.

Authors:  C Scheibenbogen; K H Lee; S Stevanovic; M Witzens; M Willhauck; V Waldmann; H Naeher; H G Rammensee; U Keilholz
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

9.  Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.

Authors:  L BenMohamed; H Gras-Masse; A Tartar; P Daubersies; K Brahimi; M Bossus; A Thomas; P Druilhe
Journal:  Eur J Immunol       Date:  1997-05       Impact factor: 5.532

10.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

View more
  13 in total

1.  Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

Authors:  Craig L Slingluff; Gina R Petroni; Walter Olson; Andrea Czarkowski; William W Grosh; Mark Smolkin; Kimberly A Chianese-Bullock; Patrice Y Neese; Donna H Deacon; Carmel Nail; Priscilla Merrill; Robyn Fink; James W Patterson; Patrice K Rehm
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

2.  Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Authors:  Sharon E Frey; Laurence Peiperl; M Juliana McElrath; Spyros Kalams; Paul A Goepfert; Michael C Keefer; Lindsey R Baden; Michelle A Lally; Kenneth Mayer; William A Blattner; Clayton D Harro; Scott M Hammer; Geoffrey J Gorse; John Hural; Georgia D Tomaras; Yves Levy; Peter Gilbert; Allan deCamp; Nina D Russell; Marnie Elizaga; Mary Allen; Lawrence Corey
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

3.  Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.

Authors:  H Gahéry-Ségard; G Pialoux; B Charmeteau; S Sermet; H Poncelet; M Raux; A Tartar; J P Lévy; H Gras-Masse; J G Guillet
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.

Authors:  Valérie Molinier-Frenkel; Renée Lengagne; Florence Gaden; Saw-See Hong; Jeannine Choppin; Hanne Gahery-Ségard; Pierre Boulanger; Jean-Gérard Guillet
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.

Authors:  Masaharu Katae; Yasushi Miyahira; Kazuyoshi Takeda; Hironori Matsuda; Hideo Yagita; Ko Okumura; Tsutomu Takeuchi; Tsuneo Kamiyama; Akihiko Ohwada; Yoshinosuke Fukuchi; Takashi Aoki
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

7.  Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: an in vitro study.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Jing Ye; Hai-Long Dong; Ping Qu; Xiu-Min Zhang; Wen-Yong Wang; Yu-Song Li
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

8.  Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells.

Authors:  Muriel Andrieu; Jean-François Desoutter; Estelle Loing; Jésintha Gaston; Daniel Hanau; Jean-Gérard Guillet; Anne Hosmalin
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251.

Authors:  Pascale Villefroy; Franck Letourneur; Zoe Coutsinos; Lorenzo Mortara; Christian Beyer; Helene Gras-Masse; Jean-Gerard Guillet; Isabelle Bourgault-Villada
Journal:  Virol J       Date:  2006-08-31       Impact factor: 4.099

10.  Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.

Authors:  Odile Launay; Christine Durier; Corinne Desaint; Benjamin Silbermann; Angela Jackson; Gilles Pialoux; Bénédicte Bonnet; Isabelle Poizot-Martin; Gustavo Gonzalez-Canali; Lise Cuzin; Suzanne Figuereido; Mathieu Surenaud; Nadine Ben Hamouda; Hanne Gahery; Jeannine Choppin; Dominique Salmon; Corinne Guérin; Isabelle Bourgault Villada; Jean-Gérard Guillet
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.